Key facts
- DepYmed’s last known valuation is $36.3M (Apr 2021).
- It has raised $14.3M across 6 recorded rounds; the latest was Seed Round ($250K) in Apr 2025.
- Notable investors include Accelerate Long Island, Cold Spring Harbor Laboratory, Jove Equity Partners, Long Island Emerging Technologies Fund, Long Island Emerging Technologies Fund (LIETF) — 8 tracked in total.
- DepYmed has filed 6 Form Ds with the SEC since 2021, most recently Apr 2025 ($250K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for DepYmed
Funding rounds
6 roundsAbout DepYmed
Developer of potent inhibitors of the enzyme designed to offer therapeutics for cancer and rare diseases. The company develops novel small-molecule phosphatase inhibitors and copper-chelating compounds targeting protein tyrosine phosphatases, with applications across cancer, Wilson's Disease, Rett Syndrome, and other metabolic and rare disease indications, enabling pharmaceutical and biotechnology stakeholders to advance therapeutic candidates into clinical development.
- Sector
- Healthcare
- HQ
- Farmingdale, NY, United States
- Founded
- 2014
- Employees
- 2
- Website
- depymed.com/
- Ownership
- Privately Held (backing)
DepYmed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DepYmed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DepYmed in its N-PORT filings yet. We sweep new filings monthly.